Search This Blog

Saturday, April 4, 2020

Telehealth, retail clinic use up in turn to lower-priced medical delivery sites

  • Consumer use of telehealth and retail clinics spiked from 2017 to 2018, while use of urgent care centers, ambulatory surgery centers and emergency rooms dropped as consumers increasingly turn to cheaper sites of care for low-acuity medical needs.
  • Telehealth use grew 12% and retail clinic use grew 10% during the time period, according to a new report from health cost nonprofit FAIR Health. At the same time, urgent care center use fell 11%, ambulatory surgery center use fell 12% and ER use fell 15%.
  • However, despite increased use of telehealth and retail clinics, use of all five places of health service has slowed overall. Retail clinics and virtual care saw growth from 2013 to 2018, but at a much slower rate compared to 2012 to 2017, FAIR Health found. Similarly, for urgent care centers, ambulatory surgery centers and ERs, growth in 2009 to 2018 was at a much slower rate than 2008 to 2017.
The report is the latest in a pile of research finding consumers are pivoting to less expensive medical delivery sites for non-urgent needs as healthcare costs continue to skyrocket in the U.S.
The need for cheaper and more easily accessible front doors to healthcare has been highlighted by the ongoing coronavirus outbreak, with virtual care in particular trumpeted as a means to ameliorate stress on doctor’s offices and health systems.
The Trump administration has scaled back regulations on telehealth use, including allowing traditional Medicare to cover virtual care visits over the phone or video using common methods like Skype or Facetime and urging states to roll back licensing restrictions on out-of-state physicians.
As a result, telemedicine vendors have seen utilization of their platforms skyrocket over the past few weeks.
The benefits of telehealth may be compounded in rural areas, where residents could be dozens of miles away from the closest doctor or hospital.
However, FAIR Health found retail clinics and telehealth both saw higher utilization in urban areas from 2017 to 2018, but that was offset by a small decrease in use in rural areas. Last year’s report found American’s use of telehealth jumped more than 50% between 2016 and 2017, outpacing the growth of all other sites.
Increased utilization of telehealth and retail clinics has the potential to lower healthcare costs on individual patients and the system as a whole. Retail clinic use overall grew by 10% from 2017 to 2018, mostly in northern states like Minnesota, Montana, New Jersey and Delaware, while virtual care usage bumped 12% in that year.
Urgent care use decreased 11%, ambulatory surgery center use fell 12%, and ER use dropped 15% from 2017 to 2018.
However, ERs accounted for more than 2% of all medical claims in 2017 and 2018, FAIR Health found. Urgent care centers accounted for more than 1% of all medical claims and retail clinics accounted for less than 0.1%, illustrating consumers selecting retail and telehealth options when they have a choice, but emergency needs will still result in a costlier visit to the ER or urgent care.
The report is based on an analysis of a database of more than 30 billion privately billed medical claims.
https://www.healthcaredive.com/news/telehealth-retail-clinic-use-increasing-in-pivot-toward-lower-priced-medic/575226/

Amgen teams up with Adaptive Bio to both treat and prevent COVID-19

After The Wall Street Journal first broke the news this week, Amgen and new partner Adaptive Biotechnologies have confirmed they are the latest pharma-biotech duo joining forces against the pandemic.
The pair, which said it will “start work immediately,” will develop fully human neutralizing antibodies targeting the COVID-19-causing virus, SARS-CoV-2, to potentially prevent or treat the disease currently infecting a million people around the globe and showing little sign of slowing down, especially in Europe and the U.S.
The collab sees the pair tap into Adaptive’s immune medicine platform to seek out virus-neutralizing antibodies and work this alongside Amgen’s expertise in immunology and antibody therapy development.

In an unusual move (but not unusual in these weird times), both said they would “finalize financial details and terms in the coming weeks” and hadn’t as yet, given the speedy nature of the tie-up.
They join the growing list of pharmas and biotechs working on treatments and vaccines for the disease. Research has ramped up massively in the past month and covers everything from repurposed antivirals to RNAi tech and using antibodies from those who have recovered to fight new treatments. It’s the latter approach Amgen and Adaptive will be going after.

In a statement, the pair explained that neutralizing antibodies defend healthy cells by interfering with the biological function of an invading virus. “These antibodies may be used therapeutically to treat someone currently fighting the disease and can be given to people who have heightened risk of exposure to SARS-CoV-2, such as healthcare workers,” the companies added.
Drilling down into the details of the pact, Adaptive will ramp up use of its high-throughput platform to “rapidly screen” the massive genetic diversity of the B-cell receptors from those that have recovered from COVID-19. This will help them quickly find antibodies they can select to neutralize SARS-CoV-2.
Then, in steps, Amgen will use its antibody engineering and drug development tech to select, develop and manufacture antibodies designed to bind to and neutralize SARS-CoV-2. Meanwhile, deCODE Genetics, an Amgen subsidiary, will provide genetic insights from patients who were previously infected with COVID-19. It’s an unusual move for Amgen, which is better known for its work in cancer.
“Working with Adaptive and using their viral-neutralizing antibody platform will expedite our ability to bring a promising new medicine into clinical trials as quickly as possible,” said Robert Bradway, chairman and chief at Amgen.
“We are extremely motivated to join forces with our trusted partner, Amgen, to tackle this global health crisis,” added Chad Robins, CEO and co-founder of Adaptive Biotechnologies. “This partnership expands our drug discovery capabilities, demonstrating the power and versatility of our immune medicine platform.”
https://www.fiercebiotech.com/biotech/amgen-teams-up-adaptive-to-both-treat-and-prevent-covid-19

Companies roll out remote COVID-19 monitoring tools to free up hospital space

Late last month, the FDA began giving developers of remote patient monitoring devices some extra leeway when it comes to making marketing claims, allowing them to pitch their use to hospitals responding to the COVID-19 crisis.
The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care. For example, a person who tested positive for the novel coronavirus but has only mild symptoms could stay at home and have their temperature, respiration and heart rates tracked wirelessly for signs of progression.
Now, LifeSignals announced that it is fast-tracking its single-use biosensor patch for COVID-19 patient monitoring. Self-affixed on the chest for five days, the showerproof device records a person’s vital signs, movement and the heart’s electrical activity with a two-channel ECG.
If stronger symptoms develop, the device and its data platform can alert healthcare workers to take additional action, while cumulative vital sign data could be used to identify geographical COVID-19 hot spots.
The company also plans to roll out an updated version of the patch that includes blood oxygen saturation tracking, slated for this June, for monitoring patients recovering in intensive care units and clearing them to be moved to other wards or off-site.
“As soon as the serious nature of the COVID-19 outbreak became apparent, we started investigating where our wireless biosensor technology could help,” said LifeSignals co-founder and CEO Surendar Magar. “We identified two key areas where healthcare systems are choked—consumers calling in about symptoms they are experiencing and lack of critical care hospital beds—and have designed these two biosensor patches which are suited for mass production.”
LifeSignals aims to move 1 million units in the next few months, Magar told FierceMedTech, under a mass-market oriented business model targeting a variety of service providers.
Elsewhere, former FierceMedTech Fierce 15 winner Spry Health launched a clinician-led monitoring service employing its previously FDA-cleared Loop wearable. The wrist-worn device remotely tracks heart rates, pulse oximetry and breathing.
“After talking to dozens of healthcare leaders over the past few weeks, it is clear many organizations are nearing their maximum capacity due to the large influx of patients showing up to emergency departments, often without meeting the necessary criteria for testing set by the CDC,” said Pierre-Jean Cobut, Spry’s co-founder and CEO.
“Clinicians can focus on the patients that need critical care, while we help monitor high-risk populations and intervene in advance of an emergency when early signs of deterioration are detected,” Cobut added. “The last thing we need now is to continue to flood the ED with avoidable visits, and possibly increase exposure to COVID-19, when care can be delivered remotely in the patient’s home.”
Patients with deteriorating symptoms will be contacted by telephone, treated remotely if possible or directed to the appropriate level of local care, the company said.
Other companies, such as UTM:Healthcare, have begun incorporating Bluetooth-enabled thermometers into the use of smartphone apps to keep people in touch with their doctors.
Meanwhile, ObvioHealth launched a virtual COVID-19 patient registry to track symptoms and immune responses across the general population.
The study will follow individuals for six months, detailing medical histories and risk factors associated with the infection and daily developments in order to provide insights for global health policy. The project includes plans to ship fingerstick blood tests to assess antibody and immune responses once they become available in the U.S., the company said.

Zentalis pulls off speedy $165M IPO amid pandemic-driven uncertainty

The new coronavirus has injected all kinds of uncertainty into the biotech world, leading companies to delay clinical trials, reorganize their pipelines and hold off on their IPOs. Not so for Zentalis Pharmaceuticals, which priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.
Zentalis will use the proceeds to develop ZN-c5, a selective estrogen receptor degrader, for the treatment of ER-positive, HER2-negative breast cancer. The company teamed up with Pfizer in May 2018 to test it alongside Pfizer’s CDK4/6 inhibitor Ibrance and expects to report data from a phase 1/2 study of the combo, as well as ZN-c5 as a single agent, later this year.
It has two other programs in the clinic: ZN-c3, which targets the WEE1 kinase to treat solid tumors, and an EGFR drug for lung cancer. The company aims to move its fourth program, which targets BCL-2 in blood cancers, into clinical trials by the middle of this year.

Zentalis spent its first few years under the radar, officially launching in December with an $85 million series C round. Just three months later—and two days before the World Health Organization (WHO) officially declared COVID-19 a pandemic—it filed to raise $100 million in its Nasdaq debut. By Bloomberg’s count, Zentalis is the second biotech company to go public in the U.S. since WHO’s declaration.

It joins Imara, a biotech working on a treatment for sickle cell disease, which began trading March 12, the day after the pandemic was declared. Unlike Zentalis, which outraised its goal by more than half, Imara took a bit of a hit, pricing its IPO at $75.2 million after taking aim at an $86 million listing.
Toward the end of 2019, industry watchers listed a number of factors that might affect the U.S. IPO market in 2020, ranging from the presidential election and changes in interest rates to Brexit and trade tensions between the U.S. and China. A pandemic was not one of them. Now, COVID-19 has “thrown a wrench in what would have been the most active period of the 2020 IPO market,” Renaissance Capital said in a report last month.
It has all but “shut down the spring IPO market,” Renaissance wrote. It now expects a “narrower IPO window in the summer, for companies relatively unaffected by the virus” and for more companies to aim for fall IPOs.
https://www.fiercebiotech.com/biotech/zentalis-pulls-off-speedy-165m-ipo-amid-pandemic-driven-uncertainty

CDC director Redford on coronavirus, masks, and an agency gone quiet

Robert Redfield, director of the Centers for Disease Control and Prevention, describes the coronavirus pandemic as the greatest public health crisis in a century.
And yet the storied agency that Redfield leads — one that has been used as a model by countries around the world, including the China CDC — has played a largely invisible role in the nation’s response since the White House took over communications about the outbreak last month.
CDC experts, who held regular briefings to update the public about previous health threats such as the H1N1 flu pandemic and the Zika outbreak, have been silenced. It has been nearly a month since the last CDC media briefing, which took place March 9.
STAT asked Redfield about the agency’s role, whether he was satisfied with it, the agency’s evolving thinking about whether people should wear cloth masks in public, and how he sees the pandemic unfolding. The conversation has been lightly edited for length and clarity.
How are you? It’s a very challenging time.
I’m doing fine.
I would like to ask you a bit about the mask issue. [After this interview with Redfield, the CDC issued guidance urging the public to wear cloth masks in public to slow spread of the disease. President Trump announced the new recommendation at a press briefing.]
We strongly continue to recommend that N95 masks and surgical masks really be committed to the health care workers that are on the frontlines. Our nation owes them all a great gratitude as they continue to confront what you and I now know is the greatest public health crisis that’s hit this nation in more than a century.
But we actually have one of the most powerful weapons that we need to defeat the spread of this virus. And I know a lot of people may not see it as a powerful weapon, but it is. And that’s social distancing. This virus cannot jump 6 feet. So this is why the president’s recommendation is to slow the spread of the coronavirus.
I want to constantly thank the American public that have taken these social distancing recommendations and operationalized them into action with vigor and vigilance. And I just want to petition the remainder to have everybody go all in. That big, powerful weapon that we have is just to stay 6 feet apart.
Now that said, there’s probably greater numbers of individuals that are without symptoms, and have this virus and can shed this virus than I think was originally appreciated. So we are discussing in detail whether a face covering, a face barrier, whether that would modify the ability of those of us that may be infected and don’t know it to actually infect others. It’s not a decision to try to protect me from getting coronavirus. It’s to help modify spreading. And there is scientific data to show that when you aerosolized virus through a cloth barrier, you have a reduction in the amount of virus that gets through the other side.
Kind of a homemade, make-it-yourself barrier, whether it’s a bandana or a scarf.
Are you going to give people some advice on what kind of fabric? Because all fabrics are not created equal. 
Obviously, there will be guidance on the fabrics, guidance on how to make them.
You mentioned earlier that the biggest tool that we have is social distancing. But it is being applied in a patchwork manner across the country. Some states have been more aggressive. Others are not. Do you think it’s time for a national stay-at-home order?
I think ultimately in these things it’s, how do you get full participation? I think you have to get the hearts and minds of people behind this. And so I think, you know, different jurisdictions will approach it in different ways. I will say what I’ve seen is the American public is embracing these strategies.
Dr. [Deborah] Birx says not enough of them. 
I think people can decide independently in these states, the governors, and the mayors, how they think they’re best going to motivate their individuals to adhere to the social distancing. My own personal view is the best way to motivate is to have them shut their eyes and see their parents’ faces, their grandparents’ faces, their neighbors that have chronic illness, children that are suffering from cancer and say, “I need you to do it for them.”
What is the next year, the next 18 months going to look like in your estimation? 
I think there’s a reasonable probability that this virus is going to have a seasonality to it. And that means that there’s a potential global catastrophe that may, in fact, be on its way to the Southern Hemisphere, particularly sub-Saharan Africa. And we need to prepare for that.
Related to us, that means that we may, in fact, get through in the weeks ahead, the months ahead into a lull. But I would say [if] we’re lucky enough to have that we need to get very prepared because next late fall and early winter, like most respiratory viruses, coronavirus 19 will be an enemy that we’re going to have to face again. Now we’re going to have time to prepare. We’re going to have, I think, hopefully time to reinforce our public health capacity in many parts of the nation so that we can do early diagnosis, isolation, contact tracing, prevent large community clusters, prevent what we call sustained community transmission. Just one of our challenges next season is going to be two simultaneous outbreaks: coronavirus 19, second wave, and our regular flu season. And they both compete for the same hospital resources.
The CDC hasn’t had a briefing in almost one month. That is extraordinary. Don’t you fear that your agency has been sidelined in this? 
No, I wouldn’t say that at all. I think we’re fully engaged in all of the decisions. If you look at CDC’s website and what we’re doing constantly in our communications …
People are not going to dive through the website and read hundreds of words. 
CDC is at the table in every decision. We’re at the task force meeting every single day. We’re giving our public health guidance and our recommendations.
We’ve got literally thousands of people working 24/7 gathering data all over this nation, not to mention sending people across this country to help with outbreak responses. So I think we’re fully engaged in the operations of the response. You know, if others seem to communicate some of that, that’s a decision that the administration can make. But I will guarantee you we’re 100% engaged 24/7 in operationalizing the response throughout this nation.
So you’re OK with the fact that the CDC hasn’t briefed for a month? 
I’m saying that we’re giving our recommendations at the highest level on a daily basis and on a daily basis we’re working 24/7 to actually operationalize the day-to-day response throughout this nation.
In this incredibly polarized time something that should be pretty basic — a virus is looking for throats to infect and it doesn’t care which way those throats vote — has become utterly polarized. Having the messaging come from the CDC, which is completely agnostic on a political basis, could strip out some of that politicalization that is just really not helpful.
I don’t think there’s any way you can even overstate how aggressively the CDC is involved throughout this nation in operationalizing the response. You know, we do think that we have a calming effect in being viewed as being basically …
But you’re invisible now, sir. Your agency is invisible.
You may see it as invisible on the nightly news, but it’s sure not invisible in terms of operationalizing this response. And all you have to do to find that is go talk to your state and territorial health departments. Go out and look at the outbreaks. Go look in the field. So I guess it depends on how you define visibility.
Who is in charge of the outbreak response at the CDC now? 
Anne Schuchat [CDC’s principal deputy director] is running the day-to-day response down at CDC.
So was Nancy Messonnier, director of the CDC’s Center for Immunization and Respiratory Diseases, sidelined? 
It was an evolution. Nancy really activated her center for the response in very early January when China probably still had less than 50 cases. But it was clear that this was going to be a broader agency wide response. Nancy is a very important technical person involved in the response.
So this has nothing to do with the fact that it was felt that she was contradicting the messaging from the White House? 
I think Nancy Messonnier is a gift to this nation. She’s a great talent. She continues to provide those talents and recommendations to the agency. She continues to run one of our most important centers for respiratory disease and immunization.
I did mean to ask you, have you had Covid-19? 
Not to my knowledge.
Have you been tested for it? 
No.
An interview with the CDC director on coronavirus, masks, and an agency gone quiet

5 ways to cope when masks run low

With hospitals in coronavirus hotspots struggling to preserve personal protective equipment (PPE), MedPage Today spoke with experts in engineering, medicine, and infection prevention on ways to extend their supply and use.
Infection preventionists spend their days “frantically searching” for PPE, teaching clinicians how to reuse masks and gowns or how to create their own, said Ann Marie Pettis, RN, BSN, president-elect of the Association for Professionals in Infection Control and Epidemiology (APIC) during a press briefing last week.
“This goes against everything we have known from the scientific evidence and what we have always taught our staff,” Pettis said.
An APIC survey released on March 27 found that among 1,140 infection preventionists across the U.S., 20% reported that their facilities have no respirators and another 28% are almost out of them. Roughly half of respondents were also almost or completely out of face shields.
That has prompted healthcare professionals and the agencies offering guidance to look hard at ways to make available supplies last longer and, in extreme situations, for workers to fabricate their own gear. In many facilities, it’s simply impossible to put on a new, fresh-from-the-box mask for every patient encounter. That means wearing them longer and/or decontaminating them.
Option 1: Extended Wear, Reuse
The CDC recommendations around optimizing the use of N95s fall into three categories: conventional, contingency, and crisis.
Already many hospitals in the contingency and crisis stages are implementing policies of extended use or limited reuse.
Kathleen Aumann Morales, PhD, RN, CNE, of Berry College in Georgia, said on a webinar hosted by The Infection Prevention Strategy (TIPS) that she has heard of nurses getting one mask per day, per week, or even every 2 weeks. Some nurses wear surgical masks over their N95 respirators to make them last longer, she noted.
In CDC guidance issued Tuesday, the agency pointed to studies demonstrating that the virus that causes COVID-19 can live on plastic, stainless steel, and cardboard surfaces for up to 72 hours.
The agency then suggested a passive decontamination strategy of sorts: issuing five respirators to each healthcare worker seeing COVID-19 patients. The worker wears each mask in the same order and places it in a paper bag at the end of the day. If done correctly, there should be a minimum of 5 days between each respirator’s repeat use, the guidance notes.
But reuse, a “contingency capacity strategy,” is not without risks: “There is perhaps something worse than no mask, and that would be self-inoculation,” said Larry Chu, MD, MS, director of the Anesthesia Informatics and Media (AIM) Lab at Stanford University Medical Center in California.
It’s easy to imagine a clinician unknowingly placing a mask that’s been stuffed in a pocket or bag and become contaminated with the COVID-19 virus up against his or her face, Chu told MedPage Today. “If we remove a mask … it may be safest to only replace it with a clean or disinfected mask,” he said. (Chu emphasized that healthcare workers should always comply with their hospitals’ policies and that his views are not necessarily those of Stanford Medicine.)
“Extended use is probably the safest way to go,” particularly for those in a designated COVID unit, Pettis told MedPage Today.
In its guidance, CDC reminds workers who reuse masks to treat respirators as though they are contaminated. Wearers should wash their hands with soap and water, use clean gloves when donning and performing seal checks, and inspect the respirator to ensure there’s no damage, particularly to the straps, nose bridge, and nose foam material, and to always avoid touching the inside of the respirator.
Pettis also noted that unused respirators that have passed the expiration dates on their labels can be used, per the CDC.
“Realistically, a lot of times expiration dates are over-cautious,” she said.
But if a respirator is “compromised” or if a seal check fails, the respirator should be discarded and replaced, the CDC advised.
Decontamination
Decontamination is in a kind of “Wild, Wild West” phase, Pettis said.
Despite there being no CDC-approved method for decontamination, the agency said ultraviolet germicidal irradiation (UVGI), vaporous hydrogen peroxide (VHP), and moist heat have shown “the most promise” as methods for decontaminating respirators.
The CDC warned that decontamination and subsequent reuse is a “crisis capacity strategy” because it may diminish a respirators’ level of protection, a CDC spokesperson told MedPage Today via email.
Changes to the respirator could reduce its filtration efficiency, its breathability, or “degrade the straps, nose bridge material, or strap attachments,” which could in turn affect how well a respirator fits, the spokesperson noted.
There isn’t specific data to support the efficacy of decontamination against the COVID-19 virus right now on respirators, and more research will be needed to confirm that the virus is “inactivated,” noted the CDC.
The FDA issued new guidance on March 29 explaining that during this public health emergency, the agency “does not intend to object to the distribution and use of sterilizers, disinfectant devices, and air purifiers that are intended to be effective at killing SARS-CoV-2 [the virus that causes COVID-19] … FDA believes such devices will not create such an undue risk, when performance and labeling criteria are met.”
Option 2: Ultraviolet Light
John Lowe, PhD, of the University of Nebraska Medical Center College in Omaha, designed a method for decontaminating N95 respirators using ultraviolet light.
The process works like this: Bags of used masks are transported to a room inside the university’s medical center fitted with two ultraviolet light towers. The respirators are labeled with the wearer’s first initial, last name, and the date of first use, and the paper bags are similarly labeled with the wearer’s full name and the unit to which the respirators should be returned.
The respirators are hung on wires across the room and decontaminated when the UV light towers are turned on. Afterwards, the respirators are returned to the original wearer.
Chu and Amy Price, DPhil, of Stanford Medicine, who recently tested five different methods of decontaminating respirators, confirmed that UVGI was “safe and effective” in the models tested. (Chu noted that Stanford’s AIM Lab COVID-19 Evidence Service Report is not intended to advocate for any product or service.)
But Pettis said that while ultraviolet germicidal irradiation may be relatively “tried and true,” it’s not an easy process: Light must reach every part of the mask and absorption levels have to be monitored, she explained, noting that her hospital, Highland Hospital of the University of Rochester in New York, has chosen hydrogen vapor peroxide instead.
“Process-wise, it was just easier and we had more confidence in the hydrogen peroxide vapor getting into everything that needed to be decontaminated,” Pettis said.
William Anderson, of the University of Waterloo Faculty of Engineering in Ontario, said on the TIPS webinar that UV radiation doesn’t appear to harm the respirator’s capacity for filtration.
Still, he said, the buildup of material as masks are used and reused could potentially make breathing more difficult.
Anderson said he was not sure how many decontamination cycles the process would allow per respirator, but Morales guessed an upper limit of five.
Option 3: Vaporous Hydrogen Peroxide
Battelle Labs, a Columbus, Ohio-based nonprofit, received an emergency use authorization from the FDA on March 28 to decontaminate N95 respirators for reuse using a VHP procedure that calls for 2.5 hours of exposure to concentrated gases and a maximum of 20 decontamination cycles per respirator.
VHP decontamination showed “minimal effect” on filtration efficacy and demonstrated “99.9999% efficiency in killing bacterial spores” and similar efficacy against bacteriophage viruses, the CDC noted in its guidance.
But the elastic bands themselves can degrade after about 30 cycles, Anderson pointed out, citing an earlier FDA report on the Bioquell HPV Decontamination system.
Anderson said that although some studies note concerns of hydrogen peroxide residue on respirators, as long as enough time is allotted for off-gassing, he does not anticipate a problem.
Overall, he called it a “feasible approach,” but expressed concerns about throughput for VHP systems that hospitals already have on site, which may take “multiple hours per batch.”
Battelle’s system, a “scaled-up version of VHP,” can handle “quite a few masks, but deployment may take a while,” he added in a follow-up email. Battelle is currently processing N95 respirator masks for OhioHealth. In addition, Stony Brook University Hospital in New York has plans to begin using Battelle’s Critical Care Decontamination System, which can disinfect up to 80,000 masks in a day, a spokesperson for the university said in an email.
Option 4: Heat
A third method of decontamination, moist heat, has been studied at 60°C and 80% relative humidity. In one study, it only minimally reduced filtration and fit of the respirator, according to the CDC, while in a second it led to a “99.99% reduction” in H1N1 influenza virus. One drawback from this method is the uncertainty around its ability to disinfect different pathogens, the agency noted.
In addition, Yi Cui, PhD, of Stanford University, and colleagues have experimental data suggesting that, although different, use of dry heat around 75°C for 30 minutes can also decontaminate N95 respirators and maintain filtration efficiency over several cycles.
But that process will require more research before it can be confirmed, he noted.
The CDC’s guidance found that decontamination with 160° C dry heat reduced the efficacy of the N95 filter and “did not meet the levels that NIOSH [the National Institute for Occupational Safety and Health] would allow for approval,” but this is twice the temperature Cui’s team studied.
The CDC guidance also noted that decontamination with an autoclave, 70% isopropyl alcohol, microwave irradiation, and soap and water resulted in “significant filter degradation.”
What Not to Do
While the PPE shortages have encouraged clinicians to be innovative, experts shared certain do’s and don’ts:
  • Do not bake a respirator in a home oven, Chu warned, as it could expose the wearer and others to the virus
  • Do not use tanning lamps or nail dryers as a source of UV radiation, Anderson said, explaining that those lamps typically use UVA radiation that have a longer wavelength and do less damage to pathogens
  • Do not randomly redistribute decontaminated respirators; clinicians should write their names on their masks and each hospital should have a system to ensure they are returned to the appropriate owner, said Chu. Masks are disinfected but not cleaned. Not only is it “disconcerting” to receive a mask with someone else’s lipstick on it, the process may have eliminated the COVID-19 virus without inactivating all other microbes
Option 5: Homemade Substitute
As a last resort, homemade masks are “better than nothing,” Morales said, but they’re more effective at “keeping the germ in than keeping the germ out.”
Chu and his colleagues assessed the filtration efficiency of different homemade materials using everything from vacuum cleaner bags to cotton T-shirts.
But as Cui pointed out, it would be impossible for a layperson to make “a high efficiency mask” with these materials.
At Pettis’ hospital, homemade masks are given to outsiders visiting patients or confirmed COVID-19 patients who are being sent home. The masks are laundered, of course, and could in the future be used by clinicians to make their own N95s last longer.
“Could we get to the point where we do have to use them for the staff? We could,” she admitted. “After this is all over, I think there will be a lot of soul-searching to figure out how to improve and prevent some of the issues that we’re facing right now.”
https://www.medpagetoday.com/infectiousdisease/covid19/85799

Covid-19: four fifths of cases are asymptomatic, China figures indicate

Michael Day
Author affiliations
New evidence has emerged from China indicating that the large majority of coronavirus infections do not result in symptoms.
Chinese authorities began publishing daily figures on 1 April on the number of new coronavirus cases that are asymptomatic, with the first day’s figures suggesting that around four in five coronavirus infections caused no illness. Many experts believe that unnoticed, asymptomatic cases of coronavirus infection could be an important source of contagion.
A total of 130 of 166 new infections (78%) identified in the 24 hours to the afternoon of Wednesday 1 April were asymptomatic, said China’s National Health Commission. And most of the 36 cases in which patients showed symptoms involved arrivals from overseas, down from 48 the previous day, the commission said.
China is rigorously testing arrivals from overseas for fear of importing a fresh outbreak of covid-19.
Tom Jefferson, an epidemiologist and honorary research fellow at the Centre for Evidence-Based Medicine at the University of Oxford, said the findings were “very, very important.” He told The BMJ, “The sample is small, and more data will become available. Also, it’s not clear exactly how these cases were identified. But let’s just say they are generalisable. And even if they are 10% out, then this suggests the virus is everywhere. If—and I stress, if—the results are representative, then we have to ask, ‘What the hell are we locking down for?’”
Jefferson said that it was quite likely that the virus had been circulating for longer than generally believed and that large swathes of the population had already been exposed.
Users of Chinese social media have expressed fears that carriers with no symptoms could be spreading the virus unknowingly, especially now that infections have subsided and authorities have eased curbs on travel for people in previous hotspots in the epidemic.
Zhong Nanshan, a senior medical adviser to the Chinese government, said that asymptomatic infections would not be able to cause another major outbreak of covid-19 if such people were kept in isolation. Officials have said this is usually for 14 days.
Nanshan said that once asymptomatic infected people were identified, they and their contacts would be isolated and kept under observation.
Citing classified data, the South China Morning Post said that China had already found more than 43 000 cases of asymptomatic infection through contact tracing.
The latest findings seem to contradict a World Health Organization report in February that was based on covid-19 in China. This suggested that “the proportion of truly asymptomatic infections is unclear but appears to be relatively rare and does not appear to be a major driver of transmission.”1
But since that WHO report other researchers, including Sergio Romagnani, a professor of clinical immunology at the University of Florence, have said they have evidence that most people infected by the virus do not show symptoms. Romagnani led the research that showed that blanket testing in a completely isolated village of roughly 3000 people in northern Italy saw the number of people with covid-19 symptoms fall by over 90% within 10 days by isolating people who were symptomatic and those who were asymptomatic.2
In an article on the website of the Centre for Evidence-Based Medicine, Jefferson and Carl Heneghan, director of the centre and editor of BMJ EBM, write, “There can be little doubt that covid-19 may be far more widely distributed than some may believe. Lockdown is going to bankrupt all of us and our descendants and is unlikely at this point to slow or halt viral circulation as the genie is out of the bottle.
“What the current situation boils down to is this: is economic meltdown a price worth paying to halt or delay what is already amongst us?”3

References

https://www.bmj.com/content/369/bmj.m1375